Effect of US Food and Drug Administration-Approved Pediatric Labeling on Dispensing of Extended-Release Oxycodone in the Outpatient Retail Setting.
Office of Public Health Strategy and Analysis, Office of Commissioner, US Food and Drug Administration, Silver Spring, Maryland.
Jing
J
Xu
Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Rajdeep
R
Gill
Office of Public Health Strategy and Analysis, Office of Commissioner, US Food and Drug Administration, Silver Spring, Maryland.
Marisa
M
Cruz
Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
Judy
J
Staffa
Office of Public Health Strategy and Analysis, Office of Commissioner, US Food and Drug Administration, Silver Spring, Maryland.
Peter
P
Lurie
D000293:Adolescent; D000701:Analgesics, Opioid / Q000600:supply & distribution*; D002648:Child; D002675:Child, Preschool; D003692:Delayed-Action Preparations; D004348:Drug Labeling / Q000331:legislation & jurisprudence*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007880:Legislation, Drug; D010098:Oxycodone / Q000600:supply & distribution*; D010146:Pain / Q000517:prevention & control; D014481:United States; D014486:United States Food and Drug Administration
D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D010098:Oxycodone